EU Policy & Law
EMA Recommends 12 New Medicines for EU Approval
The European Medicines Agency’s human medicines committee (CHMP) recommended 12 new medicines for approval at its February 2026 meeting. Key highlights include a positive opinion for Xolremdi, a treatment for the ultra-rare hereditary WHIM syndrome, and a new therapy for paediatric low-grade glioma. These recommendations represent a major expansion of treatment options for rare and childhood diseases across the EU. Following this advisory step, the European Commission will decide on the final marketing authorizations for each product.
EMA recommends 12 new treatments, including options for rare and paediatric diseases.